Kiniksa initiated with a Buy at Canaccord

Canaccord initiated coverage of Kiniksa (KNSA) with a Buy rating and $62 price target Kiniksa is a commercial-stage biotech company with a focus on developing treatments for recurrent pericarditis and additional inflammatory cardiovascular diseases, the analyst tells investors in a research note. The firm says the company’s Arcalyst is the first and currently only FDA-approved therapy for recurrent pericarditis. According to Future Market Insights, the pericarditis treatment market was estimated to be valued at $4.1B in 2025 and is projected to reach $6.8B by 2035, Canaccord points out.